



26 June 2020

## **Medicine Supply Alert Notice**

### **Lacosamide (Vimpat®) 50mg tablets (UCB Pharma Ltd)**

**Priority: Level 2\***

**Valid until: w/c 20 July 2020**

#### **Issue**

1. Vimpat® 50mg tablets will be out of stock from early July until week commencing 20th July 2020.
2. Vimpat® 10mg/ml syrup remains available.

#### **Advice and Actions**

3. Where the patient has insufficient supplies to last until the resupply date, clinicians should consider prescribing Vimpat® (lacosamide) 10mg/ml syrup which is able to support the market during this time, ensuring that the patient is not intolerant to any of the excipients and is counselled on the appropriate dose and volume required (see additional information below).
4. If the above option is not considered appropriate, advice should be sought from specialists on management options.

#### **Additional Information**

5. Vimpat® tablets and syrup are bioequivalent. Further information can be found in the SPC: <https://www.medicines.org.uk/emc/product/2285/smpc>.
6. Vimpat® syrup contains sorbitol (E420). Patients with rare hereditary problems of fructose intolerance should not take this medicine. Sorbitol may cause gastrointestinal discomfort and a mild laxative effect. The syrup also contains aspartame (E951), a source of phenylalanine, which may be harmful for people with phenylketonuria.

#### **Enquiries**

7. Enquiries from Health Boards or healthcare professionals should be directed in the first instance to [PharmacyTeam@gov.scot](mailto:PharmacyTeam@gov.scot) (primary care) or [NSS.NHSSMedicineShortages@nhs.net](mailto:NSS.NHSSMedicineShortages@nhs.net) (secondary care).